Daniela J. Cornado
Dr. Daniela Conrado has over 10 years of research experience in pre-clinical/clinical pharmacology and pharmacometrics with a focus on neuroscience. Her current focus is on advancing quantitative drug development tools for neurodegenerative diseases.
Dr. Conrado has worked on Phase 1 through Phase 4 stages supporting model-informed drug discovery and development (MID3) activities. She has published over 30 peer-reviewed journal articles and conference proceedings, and is an active member of the International Society of Pharmacometrics (ISoP) and the American Society of Clinical Pharmacology and Therapeutics (ASCPT). She is a chair of the Drug Development Tools in the Alzheimer Disease Spectrum (DDT-AD) working group of the C-Path/ISoP Neuro-Pharmacometrics Community of Practice (NeuroCoP).